Lv3
370 积分 2024-04-09 加入
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
21天前
已完结
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
21天前
已完结
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
21天前
已完结
Optimization and intra-assay validation of a multiparametric flow cytometric test for monitoring circulating TREGs
1个月前
已关闭
中国中枢神经系统胶质瘤免疫和靶向治疗专家共识
5个月前
已完结
免疫检查点抑制剂引起的内分泌系统免疫相关不良反应专家共识
7个月前
已完结
皖公网安备34019202002308
